ACCELERATING THERAPEUTICS FOR PLEXIFORM AND CUTANEOUS NEUROFIBROMAS

What We Do

The Neurofibromatosis Therapeutic Acceleration Program (NTAP) is focused exclusively on improving treatment options for people living with Neurofibromatosis type 1-related plexiform neurofibromas. With the goal of therapeutics always in mind, initiatives span research that probes the basic aspects of tumorgenesis through clinical investigations of drugs that have the highest likelihood of having a positive impact for patients. NTAP’s approach is defined by (1) intense collaboration both within and outside of the neurofibromatosis research community and (2) ongoing critical assessment of the existing needs and opportunities for developing effective plexiform neurofibroma therapeutics.

————————————————————————————————————————————————–

 

NEW CLINICIAN-SCIENTISTS CHOSEN FOR NEUROFIBROMATOSIS AWARD, RESEARCH SUPPORT

NTAP is pleased to announce the selection of Drs. Tamar Green and Steven Rhodes as the 2020 Francis Collins Scholars. The next call for applications will be released in July 2020 with a December 21, 2020 due date.

News

With Food and Drug Administration (FDA) approval, selumetinib is now the first effective treatment for children with NF1 associated plexiform neurofibromas that can’t be removed by surgery. Decades of collaborative research culminated in clinical trials of selumetinib for symptomatic plexiform neurofibromas in children with NF1 that showed unpredicted activity.

Partner with NTAP

NTAP partners with key stakeholders in plexiform and cutaneous neurofibroma therapeutic research to ensure efforts are synergistic and have the greatest possible impact.

The next call for Francis Collins Scholars applications will be released in July 2020 with a December 21, 2020 due date.